Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes
Executive Summary
In an interview, Acting Office of Generic Drugs Director Kathleen Uhl says reviewers need practice before the formal clock begins with October submissions.
You may also be interested in...
US FDA Generic Drug Office Director Uhl Announces Retirement
Uhl, who shepherded OGD into the user fee era, will retire in February.
US FDA Generic Drug Office Director Uhl Announces Retirement
Uhl, who shepherded OGD into the user fee era, will retire in February.
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Implementer of many drug review changes will leave in January after nearly 32 years of public service.